Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Par Aims To Add Branded Products After Merck KGaA Divests Equity Stake

Executive Summary

Par is looking to add branded products to its portfolio as it seeks to join the top-tier independent generic drug companies after Merck KGaA divests its controlling interest in the firm.
Advertisement

Related Content

Barr Eyes Oncology For Branded Acquisitions Beyond Women’s Health
Barr Eyes Oncology For Branded Acquisitions Beyond Women’s Health
Par Responds To Process Patents: FineTech Acquisition Valued At $109 Mil.
Par Responds To Process Patents: FineTech Acquisition Valued At $109 Mil.
Duramed Verapamil Production Resumption Expected Within Several Months
Duramed Verapamil Production Resumption Expected Within Several Months
Mylan merger speculation
Dr. Reddy's Looks To Acquire U.S. Generics Company Following $115 Mil. IPO
Par 7.5 Mg Buspirone Aims To Capture Portion of 15 Mg Split-Tablet Market
Merck KGaA's Lindolrestat Expected To Move To Phase II In 2001
Advertisement
UsernamePublicRestriction

Register

PS038413

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel